As a consequence, the use of a Gal-3 inhibitor could provide effective and nontoxic therapy in combination with currently used ICP inhibitors or other immunotherapy strategies to boost immune infiltration and responses in NSCLC. This evidence concerns the gene LGALS3 and non-small cell lung carcinoma.